TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025

DBV Technologies announced positive topline results from its Phase 3 VITESSE trial evaluating VIASKIN® Peanut Patch for treating peanut allergies in children aged 4-7 years. The trial met its primary endpoints, representing a significant milestone for the company's immunotherapy treatment program.

Insights
DBVT   positive

The company announced positive topline results from a Phase 3 clinical trial, which is a significant regulatory and clinical achievement. Meeting primary endpoints in a late-stage trial typically supports potential regulatory approval and commercialization prospects for the therapeutic candidate.